Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AEMD Aethlon Medical

Pre-Market Trading 01-24 07:46:40 EST

0.6650

+0.0482

+7.81%

盘前0.6517

-0.0133-2.00%

06:55 EST

High0.6650	Low0.6150	Vol508.82K
Open0.6150	D1 Closing0.6168	Amplitude8.11%
Mkt Cap9.28M	Tradable Cap9.21M	Total Shares13.96M
T/O322.90K	T/O Rate3.67%	Tradable Shares13.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AEMD","market":"US","secType":"STK","nameCN":"Aethlon Medical","latestPrice":0.665,"timestamp":1737666000000,"preClose":0.6168,"halted":0,"volume":508824,"hourTrading":{"tag":"盘前","latestPrice":0.6517,"preClose":0.665,"latestTime":"06:55 EST","volume":3000,"amount":1955.1,"timestamp":1737719755795},"delay":0,"floatShares":13845613,"shares":13961998,"eps":-1.696862,"marketStatus":"Pre-Market Trading","change":0.0482,"latestTime":"01-24 07:46:40 EST","open":0.615,"high":0.665,"low":0.615,"amount":322902.61069680005,"amplitude":0.081064,"askPrice":0.695,"askSize":100,"bidPrice":0.5954,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.696862,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1737729000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.665,"preHourTrading":{"tag":"盘前","latestPrice":0.6517,"preClose":0.665,"latestTime":"06:55 EST","volume":3000,"amount":1955.1,"timestamp":1737719755795},"postHourTrading":{"tag":"盘后","latestPrice":0.665,"preClose":0.665,"latestTime":"19:52 EST","volume":15336,"amount":10148.607102,"timestamp":1737679972023},"volumeRatio":0.5381286571151579,"impliedVol":3.8125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AEMD/wiki","defaultTab":"wiki","newsList":[{"id":"2501778865","title":"BRIEF-Aethlon Medical Granted 180-Day Extension To Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2501778865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501778865?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:16","pubTimestamp":1736345782,"startTime":"0","endTime":"0","summary":"BRIEF-Aethlon Medical Granted 180-Day Extension To Regain Nasdaq ComplianceJan 8 (Reuters) - Aethlon Medical Inc AEMD.O:AETHLON MEDICAL INC - GRANTED 180-DAY EXTENSION TO REGAIN NASDAQ COMPLIANCE WITH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O40TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4082","AEMD","BK4568"],"gpt_icon":0},{"id":"2501722381","title":"Aethlon Medical Inc - Granted 180-Day Extension to Regain Nasdaq Compliance With Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2501722381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501722381?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:26","pubTimestamp":1736342760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O40TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4568","AEMD","BK4082"],"gpt_icon":0},{"id":"2492443656","title":"Aethlon Medical provides update on availability of Hemopurifier device","url":"https://stock-news.laohu8.com/highlight/detail?id=2492443656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492443656?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:10","pubTimestamp":1734700214,"startTime":"0","endTime":"0","summary":"Aethlon Medical (AEMD) provided a statement of its investigational medical device with respect to H5N1 avian influenza “Bird Flu.” The company stat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aethlon-medical-provides-update-on-availability-of-hemopurifier-device?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aethlon-medical-provides-update-on-availability-of-hemopurifier-device?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4568","BK4082","AEMD"],"gpt_icon":0},{"id":"2492144835","title":"Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5n1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2492144835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492144835?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:01","pubTimestamp":1734699662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA2TW8Q8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4082","AEMD","BK4568"],"gpt_icon":0},{"id":"2492051446","title":"Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2492051446","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492051446?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:01","pubTimestamp":1734699660,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec. 20, 2024 /PRNewswire/ --Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza \"Bird Flu.\". Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including a case of severe infection in Louisiana, and yesterday's declaration of a state of emergency in California.While the Aethlon Hemopurifier has not yet been used to treat patients with severe influenza, including those infected with H5N1, it has been used in 38 patients across 164 distinct treatment sessions, targeting diseases such as hepatitis C, HIV, and in patients critically ill due to COVID-19 and Ebola. The Hemopurifier ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2iQmTdaG7cFlKIdUCDemtg--~B/aD0xMzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c685534e48e0872c689325d5016541a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2iQmTdaG7cFlKIdUCDemtg--~B/aD0xMzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c685534e48e0872c689325d5016541a6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-provides-ability-hemopurifier-130100302.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-provides-ability-hemopurifier-130100302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","ABIL","BK4568","AEMD","IDE","BK4583"],"gpt_icon":0},{"id":"2488916561","title":"Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916561","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916561?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"MIAMI, Dec. 03, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-77-120000303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4076","BK4109","BK4139","BK4182","MNQmain","ATRA","BK4213","NQmain","BK4583","BENFW","BVAXF","WRLGF","PCYO","BK4503","AEMD","ASPI","BK4021","BENF","BK4191","OPWEF","SKYH","QLD","JAGX","BK4082","UCAR","RERE","BK4122","ICON","LUCMF",".IXIC","BK4579","MTVA","TQQQ","BK4017","VIOT","QID","ELRRF","BNRG","STXPF","BK4568","WINT","BK4214","BIXT","USEG","LGVN","NRXBF","PSQ","XBOTF","SQQQ"],"gpt_icon":1},{"id":"2483320455","title":"Maxim Group Sticks to Their Hold Rating for Aethlon Medical (AEMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483320455?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:35","pubTimestamp":1731674152,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Anthony Vendetti maintained a Hold rating on Aethlon Medical (AEMD – Research Report) yesterday. The company’s shares closed ye...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-hold-rating-for-aethlon-medical-aemd-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-hold-rating-for-aethlon-medical-aemd-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AEMD"],"gpt_icon":0},{"id":"2483192322","title":"Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483192322","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483192322?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:12","pubTimestamp":1731672720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AEMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 07:12 ET (12:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2483884313","title":"Aethlon’s Future at Risk: Financial Struggles, Stockholder Dilution, and Market Challenges Loom","url":"https://stock-news.laohu8.com/highlight/detail?id=2483884313","media":"TIPRANKS","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483884313?lang=en_us&edition=fundamental","pubTime":"2024-11-15 14:02","pubTimestamp":1731650525,"startTime":"0","endTime":"0","summary":"Aethlon (AEMD) has disclosed a new risk, in the Accounting & Financial Operations category. Aethlon faces significant financial and operational ris...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlons-future-at-risk-financial-struggles-stockholder-dilution-and-market-challenges-loom?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlons-future-at-risk-financial-struggles-stockholder-dilution-and-market-challenges-loom?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4583","BK4082","AEMD"],"gpt_icon":0},{"id":"2483336682","title":"AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2483336682","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483336682?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:09","pubTimestamp":1731593340,"startTime":"0","endTime":"0","summary":"Patient enrollments begin for AEMD’s basket oncology trial. Aethlon Medical  announced FY 2Q results and provided a business update yesterday. The company has made significant strides in moving its clinical activities forward over the past few weeks. The company has enrolled the first two patients in its oncology trial  at the Royal Adelaide Hospital in Australia. Another site that will participate in the study, Pindara Private Hospital in Australia, has also received ethics committee approval and training on the Aethlon Hemopurifier and is now initiating patient enrollment. The company has also trained staff at a third hospital in Australia and expects this facility to receive formal ethics committee approval in the near-term and begin patient enrollments. Overall, we present our key takeaways in this note.Lead asset the Aethlon Hemopurifier is being evaluated in combination with checkpoint inhibitors as a potential treatment for patients suffering from various solid tumor types. With","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aemd-oncology-trial-moves-forward-140900065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEMD","BK4583","BK4202","FORD","BK4568","BK4082"],"gpt_icon":0},{"id":"2483887749","title":"Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2483887749","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483887749?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Looking at the harsh reality of the rise of cancer globally, the BBC reported earlier this year, \"One study found that the global incidence of early-onset cancer had increased by 79% between 1990 and 2019, with the number of cancer-related deaths in younger people rising by 29%. Another report in The Lancet Public Health described how cancer incidence rates in the US have steadily risen between the generations across 17 different cancers, particularly in Generation Xers and Millennials.\". Yesterday, Aethlon Medical, Inc.  reported financial results for its fiscal second quarter e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","LU0124384867.USD","LU0724618433.USD","ON","LU2360107325.USD","BK4006","LU1548497426.USD","IE00B7SZL793.SGD","BK4585","IE00BD6J9T35.USD","LU1861215975.USD","BK4231","CRS","LU0348723411.USD","IE00B66KJ199.SGD","BK4230","BK4512","CAR","CTOS","LU1720051017.SGD","BK4080","LU1854103824.USD","BK4568","CAGR","IE00B19Z4B17.USD","BK4104","IE0031619046.USD","LU2298322129.HKD","BK4022","IE00BZ199S13.USD","BK4588","LU1861219969.SGD","SITC","LU1861214812.USD","BK4141","BK4159","AEMD","LU1978683503.SGD","LU1720051108.HKD","LU1861220033.SGD","LU1854104046.USD","LU2357305700.SGD","BK4583"],"gpt_icon":1},{"id":"2483841979","title":"Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483841979","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483841979?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:14","pubTimestamp":1731568451,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Aethlon Medical Inc  has made significant progress in its oncology trial efforts in Australia, enrolling the first two patients and opening a second hospital for patient enrollment.The company has successfully reduced its operating expenses by approximately $300,000, primarily through a decrease in professional fees.The company holds a cash balance of approximately $6.9 million, providing a solid financial foundation for ongoing research and development.There was an increase of approximately $200,000 in payroll and related expenses, largely due to separation expenses following an executive termination and workforce reduction.General and administrative expenses increased by $100,000, mainly due to costs related to the ongoing oncology clinical trial.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZzEg8dYXtXKoZ2QCPcz6MQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a40ced4714fddaddbb23f16db7f4e666","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZzEg8dYXtXKoZ2QCPcz6MQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a40ced4714fddaddbb23f16db7f4e666"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-inc-aemd-q2-071411387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRGS","AEMD"],"gpt_icon":0},{"id":"2483189467","title":"Aethlon Medical Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483189467","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483189467?lang=en_us&edition=fundamental","pubTime":"2024-11-14 11:54","pubTimestamp":1731556442,"startTime":"0","endTime":"0","summary":"* Aethlon Medical Inc    reported a quarterly adjusted loss of 20 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.22.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2483759865","title":"Aethlon Medical Advances Oncology Trials and Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2483759865","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483759865?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:54","pubTimestamp":1731534899,"startTime":"0","endTime":"0","summary":"Aethlon Medical ( ($AEMD) ) just unveiled an update. Aethlon Medical, Inc. has reported significant advancements in its oncology trials, enrolling ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-advances-oncology-trials-and-global-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-advances-oncology-trials-and-global-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AEMD","BK4568","BK4583","BK4082"],"gpt_icon":0},{"id":"2483659748","title":"Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483659748","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483659748?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:53","pubTimestamp":1731534804,"startTime":"0","endTime":"0","summary":"Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 83.61 percent increase over losses of $(1.22) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41956762/aethlon-medical-q2-2025-gaap-eps-0-20-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2483086878","title":"Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483086878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483086878?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1NGZQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4082","BK4568","AEMD"],"gpt_icon":0},{"id":"2483658008","title":"Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483658008","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483658008?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532500,"startTime":"0","endTime":"0","summary":"Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies. Two Australian Sites Open For Patient Enrollment in Hemopurifier Cancer Trial. SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.During the second quarter, and subsequently, the company advanced its oncology trial efforts in Australia, while implementing cost-cutting measures to streamline operations. Management is pleased to report positive progress on these initiatives, specifically:. Clinical Trials: The first two patients have now been enrolled at the Royal Adelaide Hospital in Adelaide, Australia. Additionally, Pi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xP9CteM8zMY0_9pwo97hUg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/595e59be0e7283e22cffb3f1ff640cb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xP9CteM8zMY0_9pwo97hUg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/595e59be0e7283e22cffb3f1ff640cb9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-announces-financial-results-211500908.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-announces-financial-results-211500908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","BK4583","AEMD","BK4568","IDE"],"gpt_icon":0},{"id":"2482088796","title":"Innovative Medical Technology Advances with First Patient Enrollments","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088796","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088796?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.According to Statista.com, \"The Medical Technology market, which encompasses various markets, including Medical Devices, is anticipated to witness significant revenue growth in the coming years.\". \"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024. Furthermore, the Medical Technology market is expected to demonstrate a steady annual growth rate of 5.29% from 2024 to 2029.\". \"Enrollment of the first patient represents the achievement of a critical milestone for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/innovative-medical-technology-advances-first-130000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innovative-medical-technology-advances-first-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","AEMD","BK4568","IDE","BK4583"],"gpt_icon":1},{"id":"2482771493","title":"Aethlon Medical Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482771493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482771493?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:45","pubTimestamp":1731383117,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc  expected to post a loss of19cents a share - Earnings Preview Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show no change in quarterly revenue when it reports  results on Nove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2482784514","title":"Aethlon Medical Enrolls First Patient in Hemopurifier Trial -- Shares Up 14% Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2482784514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482784514?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:41","pubTimestamp":1731332507,"startTime":"0","endTime":"0","summary":"Aethlon Medical  said Monday that the first patient has been enrolled in an Australian clinical trial of its immunotherapeutic device Hemopurifier to treat patients with solid tumors.The company said the trial will treat patients who have stable or progressive disease while receiving anti-PD-1 monotherapy, such as Keytruda or Opdivo.Aethlon said the first patient will receive anti-PD-1 therapy within the next two months, when concentrations of extracellular vesicles and anti-tumor T cell activity will be measured.Shares of Aethlon Medical were up 14% in recent premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AEMD","BK4568","BK4583","BK4082"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aethlonmedical.com","stockEarnings":[{"period":"1week","weight":-0.0693},{"period":"1month","weight":0.1676},{"period":"3month","weight":0.7733},{"period":"6month","weight":0.8095},{"period":"1year","weight":-0.6518},{"period":"ytd","weight":-0.2267}],"compareEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.053},{"period":"6month","weight":0.12},{"period":"1year","weight":0.2562},{"period":"ytd","weight":0.0404}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.401801},{"month":2,"riseRate":0.111111,"avgChangeRate":-0.149923},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.101527},{"month":4,"riseRate":0.111111,"avgChangeRate":-0.123823},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.137562},{"month":6,"riseRate":0.888889,"avgChangeRate":0.28379},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.094145},{"month":8,"riseRate":0.2,"avgChangeRate":-0.128305},{"month":9,"riseRate":0.4,"avgChangeRate":-0.032528},{"month":10,"riseRate":0.2,"avgChangeRate":-0.092625},{"month":11,"riseRate":0.5,"avgChangeRate":0.013975},{"month":12,"riseRate":0.5,"avgChangeRate":0.056636}],"exchange":"NASDAQ","name":"Aethlon Medical","nameEN":"Aethlon Medical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aethlon Medical,AEMD,Aethlon Medical股票,Aethlon Medical股票老虎,Aethlon Medical股票老虎国际,Aethlon Medical行情,Aethlon Medical股票行情,Aethlon Medical股价,Aethlon Medical股市,Aethlon Medical股票价格,Aethlon Medical股票交易,Aethlon Medical股票购买,Aethlon Medical股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction